Načítá se...
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
Rucaparib is a potent small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) proteins (PARP-1, PARP-2 and PARP-3) that play an important role in repairing DNA damage and maintaining genomic stability. Tumors with mutations in BRCA1/2 or other homologous recombination deficiency (HRD) genes...
Uloženo v:
| Vydáno v: | Drug Des Devel Ther |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5868608/ https://ncbi.nlm.nih.gov/pubmed/29606854 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S130809 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|